Articles tagged with Pancreatic Cancer
Researchers from Japan and the US share new technologies and blood biomarkers to detect pancreatic cancer and identify high-risk individuals. The findings aim to decrease cancer mortality rates by developing attractive new methods for early diagnosis.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
Researchers at Yale University have discovered a potentially effective treatment for advanced pancreatic neuroendocrine tumors, with a combination of capecitabine and temozolomide yielding longer progression-free survival rates and higher response rates than temozolomide alone.
The new guidelines expand indication for screening to all with BRCA 1/2 gene variations, increasing chances of early detection and treatment. The guidelines also acknowledge potential downsides of screening, including false-positive results and encourage careful patient counseling.
Researchers found that combining chemotherapy with immunotherapy increased one-year survival rates for patients with advanced pancreatic cancer, with anti-PD-1/chemo regimen showing the highest response. The study identified key immune system biomarkers associated with better outcomes, offering new hope for precision oncology.
A new study finds that cancer patients are at a greater risk of developing diabetes, particularly those with lung, pancreatic, breast, brain, urinary tract, or uterine cancers. The study also shows that cancer patients who develop diabetes die sooner than survivors without diabetes.
A study found that high fat diets and synthetic substances in unregulated athletic performance enhancers can activate a receptor accelerating the progression of pre-cancerous lesions to pancreatic cancer in mice. Limiting exposure to these substances may help prevent pancreatic cancer development.
Adding diffusion-weighted MRI to conventional MRI enhances the differentiation of locally recurrent tumor and post-surgical fibrosis in pancreatic ductal adenocarcinoma resection. The study found higher sensitivity with DWI, facilitating earlier detection of recurrences.
A study has found that patients with pancreatic ductal adenocarcinoma (PDAC) are six times more likely to have had gallstone disease within the year prior to diagnosis than non-cancer patients. This association suggests that gallstones could be a warning sign for this aggressive and deadly cancer.
Research suggests gallstone disease may be an early indicator of pancreatic cancer, with patients having gallstones nearly six times more likely to develop the disease. This association could lead to earlier diagnosis and treatment, potentially improving survival rates for pancreatic cancer patients.
UTSW researchers have identified a subset of cancer-associated fibroblasts that can be targeted to enhance immunotherapy in pancreatic cancer patients. The study found that these cells, known as antigen-presenting cancer-associated fibroblasts (apCAFs), interact with immune cells by displaying proteins called antigens on their surface.
Researchers at Oregon State University have discovered a promising approach to treating pancreatic cancer, which has a low survival rate. The study found that a liposomal prodrug outperformed traditional treatments in cancer cell cultures and animal models.
A new study from University of Gothenburg found that men with high childhood BMI are at an elevated risk of obesity-related cancer, even if their weight is normal in young adulthood. The study analyzed data from 6,565 men born between 1945 and 1961 and found a persistently increased risk of adult obesity-related cancer.
Canada's cancer rates are declining overall, but new cases and deaths are on the rise due to an aging population and growing numbers. Despite this, efforts in cancer prevention, screening, early detection, and treatment have led to improved survival rates for those diagnosed with cancer.
Researchers at Cedars-Sinai have developed an AI tool that accurately predicts pancreatic cancer patients based on CT scan images. Lowering blood cholesterol has also been shown to slow the growth of prostate cancer by enhancing immune cell action. Additionally, a new study found that an ultrasound probe plugged into a smartphone can b...
A new study indicates that artificial intelligence can accurately predict who will develop pancreatic cancer based on pre-diagnostic CT scan images. The AI tool was trained to analyze textural differences in the pancreas and achieved an accuracy rate of 86% in identifying those who would eventually develop the disease.
Researchers discovered that sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances cancer cell invasion. ST6Gal-I, an enzyme that adds sialic acid to EGFR, plays a key role in tumor progression and metastasis.
Researchers identified estrogen-related receptor gamma (ERR γ) as crucial for preventing pancreatic auto-digestion in mice. In humans, lower levels of ERR γ were found in cells affected by pancreatitis. These findings suggest new therapies regulating ERR γ activity could help prevent or treat these conditions.
The Lustgarten Foundation has awarded a $5 million grant to Break Through Cancer to target KRAS in pancreatic cancer. The Conquering KRAS in Pancreatic Cancer Team will integrate clinical and laboratory approaches to understand why patients respond to new therapies.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
The Lustgarten Foundation has awarded Career Development Grants to Pingping Hou and Edwin Manuel to fund research on pancreas cancer. Their projects focus on immune cell populations and nutrient uptake by cancer cells, aiming to develop novel therapies.
Researchers at Columbia University are studying the effects of heavy ion radiation therapy on hard-to-treat cancers, aiming to improve treatment outcomes. The new linac booster will help scientists better understand how carbon ions work against cancer, potentially leading to more effective therapies.
An AI model developed by researchers identified a subset of individuals with a 25-fold risk of developing pancreatic cancer within three to 36 months. The model used sequence of medical diagnoses from patient records to predict risk, which was validated in two independent datasets.
Dr. Philip D. Greenberg has been elected as the American Association for Cancer Research President-Elect for 2022-2023. He will work to harness advances in cancer research and translate them for patient benefit, with a focus on addressing disparities in minority engagement.
Researchers found that pancreatic cancer cells trigger the breakdown of collagen proteins, which increases arginine levels and signals stellate cells to build fibrotic meshes around tumors. This process, known as desmoplasia, creates a dense environment that promotes aggressive growth and blocks access to therapies.
Researchers have discovered two distinct classes of cancer-associated fibroblasts that accumulate in the pancreatic tumor microenvironment and play opposing roles. The study suggests that targeting these unique cell populations may improve treatment outcomes for pancreatic cancer patients.
Dr. Tony Hunter's groundbreaking work on protein tyrosine phosphorylation has led to the development of targeted cancer therapies and a deeper understanding of cancer biology. His discovery has been recognized with numerous awards, solidifying his legacy in cancer research.
Scientists at Albert Einstein College of Medicine have developed a novel therapeutic strategy that uses bacteria to deliver tetanus toxin into pancreatic tumor cells, inducing an immune response and killing the cancer. The treatment has shown promise in reducing cancer metastases by 87% and increasing mouse lifespan by 40%.
A novel screening platform has successfully detected over 95% of stage 1 pancreatic cancers using artificial intelligence-enabled protein marker analysis, outperforming current liquid biopsy tests in accuracy. This technology holds promise for early cancer detection and reducing mortality from this deadly disease.
A ketogenic diet has been shown to starve pancreatic cancer cells and enhance the effectiveness of a triple-drug therapy. The study, led by TGen, found that the diet reduced glucose levels in tumors and elevated ketone bodies, leading to increased stress on cancer cells.
A new clinical trial, named after Dr. Nate Nieto, aims to test the efficacy of a Vemurafenib and Sorafenib combination against advanced pancreatic cancer. The trial will involve about 10 patients with specific KRAS gene mutations, using liquid biopsy blood tests to identify different types of mutations.
A new study found that dual-eligible patients for Medicare and Medicaid have poorer outcomes and higher costs after cancer surgery, even in high-quality hospitals. These patients are more likely to experience complications, longer hospital stays, and lower chances of going home instead of a nursing facility.
Researchers have discovered that cancer cells carrying a common mutation accumulate large amounts of ferrous iron, which can be exploited to deliver powerful anticancer drugs. The therapeutic strategy could treat various cancers driven by KRAS mutations.
Researchers have identified a genetic signature of 27 microorganisms in stool samples that can predict the risk of pancreatic ductal adenocarcinoma and diagnose patients with earlier stages of the disease. This breakthrough could lead to an effective, non-invasive way to detect pancreatic cancer early.
Researchers identified a molecular signature of 27 microorganisms in stool samples that can predict pancreatic ductal adenocarcinoma risk and diagnose earlier stages. The study suggests a non-invasive, rapid, and affordable diagnostic kit could be developed to detect the disease.
Research suggests that changes in the microbiome may play a role in both the development and progression of pancreatic cancer. A distinct gut microbial profile was observed in patients with ductal pancreatic cancer compared to those without the disease, and this signature consistently identified patients regardless of disease stage.
Researchers have discovered a new treatment that blocks inflammation in pancreatic cancer, making it sensitive to chemotherapy and immunotherapy. The therapy more than doubled survival rates in mice with pancreatic cancer, providing promising results for future human trials.
A team of researchers from Charité – Universitätsmedizin Berlin have elucidated the process underlying drug resistance in aggressive pancreatic cancer. They found that inhibition of the RUNX1 protein limits cancer growth and may lead to effective treatment options.
A new study suggests that common blood pressure medications can prolong survival for pancreatic cancer patients. The study found that patients who took ARB-type therapies and ACE inhibitors had a lower risk of mortality compared to those who did not.
Researchers discovered that cancer cells use a combination of proteins to repel T cells and protect themselves from the immune system. By disabling this protection, scientists were able to allow T cells to infiltrate and attack pancreatic tumors, leading to shrinkage or disappearance.
A Toronto study found that certain probiotic bacteria can alter the function of immune cells and spur cancer growth in pancreatic cancer. Deletion or inhibition of a key protein enabled better treatment sensitivity and more inflammatory T cells, while activation thwarted these effects.
Researchers at the University of Illinois Chicago have developed a compound that may offer hope for pancreatic cancer treatment. The experimental compound, XP-524, has been shown to more than double the average survival time for mice with pancreatic cancer when combined with immunotherapy.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers have designed a nanoparticle system that can deliver fluorescent dyes to diagnose and treat pancreatic cancer tumors. The system overcomes the challenge of reaching cells deep within dense tumor masses, enabling detailed images of tumor structures and potentially targeted therapies.
A recent study has found that faulty versions of the BRCA1 and BRCA2 genes are associated with an increased risk of developing prostate and pancreatic cancers in men. The study analyzed data from over 3,200 families and estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by age 80.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
Researchers used optical imaging to study the metabolic interactions between pancreatic cancer cells and surrounding non-cancer cells. They found that cancer cells can hijack the metabolic activity of these non-cancer cells to fuel tumor growth. This discovery could lead to new therapies targeting the tumor microenvironment.
A new review suggests that moderate coffee consumption can stimulate digestive processes and help movement through the colon. The study also found a possible association between coffee consumption and reduced risk of gallstones and certain liver diseases. However, further research is needed to confirm these findings.
Jonsson Comprehensive Cancer Center researchers have identified signaling mechanisms in pancreatic cancer cells that could be targeted for treatment. By inhibiting a specific protein, cancer cells' DNA can become damaged and induce programmed cell death, providing a potential new strategy for treating this aggressive form of cancer.
Researchers have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy, reducing tumor size by about half and improving survival rates. The combination of ATI-450 with chemotherapy also mitigates side effects, including nausea and fatigue, in mice with human pancreatic cancer cells.
A study published in eLife reveals that a small signalling protein called ARL4C is overexpressed in pancreatic cancer patients, facilitating their aggressive behavior. By inhibiting ARL4C, researchers have shown promise in reducing the spread of pancreatic cancer cells, opening up new therapeutic avenues.
Researchers at Karolinska Institutet found that certain bacteria from the digestive system can cause damage to pancreatic cells, increasing the risk of malignant tumours. The study suggests that antibiotics could prevent this damage, offering a potential prophylactic intervention.
Researchers have identified two new symptoms – thirst and dark urine – associated with pancreatic cancer, which could help doctors diagnose the disease earlier. The study found 23 symptoms linked to pancreatic cancer, with patients often experiencing non-specific symptoms up to a year before diagnosis.
Researchers discovered that pancreatic injury leads to the formation of new cell types that can give rise to cancerous mutations. The study provides a valuable resource for understanding the processes behind pancreatic cancer and potential therapeutic targets.
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.
A new TGen study is exploring the use of checkpoint inhibitors to treat pancreatic cancer by modulating the tumor microenvironment and rendering it vulnerable to immunotherapies. The study, funded with a $1 million grant, aims to overcome the resistance of pancreatic cancer to treatments, including immune therapies.
The MUSC Hollings Cancer Center researchers are exploring the role of macroenvironment in pancreatic cancer-induced cachexia to address this debilitating condition. The team aims to provide new biological insight, which will be coordinated by four cores within the program project grant.
A study found that plasma cell-free miR-181c and tissue expression of miR-21, -210 accurately diagnose pancreatic adenocarcinoma (PA) with high accuracy. Further research is needed to validate its utility as a biomarker for PA diagnosis and monitoring.
Researchers have developed a new approach to deliver therapeutic nucleic acids using nanoparticles coated with antibodies. This system targets cancer cells while sparing normal cells, showing improved efficacy and reduced toxicity compared to previous methods.
Researchers used Caenorhabditis elegans to detect very-early-stage pancreatic cancer, achieving a reported sensitivity of 95.8%. The method showed promise for use in detecting patients with early PDAC, but the underlying mechanisms need further clarification.